Joshua Salazar

Clinical Medical Physicist at Comprehensive Cancer Centers of Nevada

Joshua Salazar is a Clinical Medical Physicist currently working at Comprehensive Cancer Centers of Nevada. Prior to this, they gained experience as a Medical Physics Resident at Geisinger and as a Medical Physics Intern at the University of Arizona: Banner Health Care. They also have experience as a Research Assistant in atomic spectroscopy and graphene engineering labs. Additionally, they have a background as a Martial Arts Instructor and volunteered at Lutheran Braille Workers Inc. They hold a Master's degree in Health/Medical Physics from the University of Arizona and a Bachelor of Science in Physics from the University of California, Riverside.

Location

Las Vegas, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Comprehensive Cancer Centers of Nevada

Comprehensive Cancer Centers of Nevada is the award-winning multi-specialty practice comprising medical oncology, hematology, radiation oncology, breast surgery, pulmonary medicine, cancer genetic counseling and clinical research with treatment centers and offices throughout Southern Nevada. Comprehensive has provided oncology services to Southern Nevada residents and visitors for more than 40 years. The practice’s specialized physician and nursing staff offers sophisticated diagnostic tools, the latest advances in cancer treatment, a full range of innovative, exclusive services and research-based care in a supportive and caring environment. In order to provide patients the most progressive and effective cancer treatments, Comprehensive expanded its clinical research program by partnering with some of the world’s most recognizable research and cancer-fighting organizations. In 1995, Comprehensive physicians became part of The US Oncology Network, one of the nation’s largest networks of community-based oncology physicians dedicated to advancing cancer care in America. Today, Comprehensive participates in more than 170 Phase I, Phase II and Phase III clinical research studies each year, and has helped develop more than 100 FDA approved cancer therapies including approvals for Hercepin, Provenge, TECENTRIQ®, Xofigo, Keytruda and others.


Employees

501-1,000

Links